Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 6071-6080 Newer>

BusinessWeek December 9, 2009 Kelley & Torsoli	Major Surgery at Sanofi CEO Chris Viehbacher has been on a buying spree and a charm offensive, both of which are reversing the drugmaker's losing streak.
Chemistry World December 9, 2009 Sarah Houlton	New hep C breakthrough A drug being developed by Denmark's Santaris Pharma could provide a breakthrough in the treatment of hepatitis C, and positive results in a study on chimpanzees point to its potential to avoid drug resistance.
The Motley Fool December 9, 2009 Brian Orelli	Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
The Motley Fool December 8, 2009 Brian Orelli	Early and Often: A Drug Investor's Dream Celgene has two goals for its multiple myeloma drug, Revlimid: to have patients begin taking it earlier in the progression of their disease, and to have them stay on the drug longer.
Inc. December 1, 2009 Nadine Heintz	Innovation: Giving Sight to the Blind A retinal implant that uses video to let the blind see.
The Motley Fool December 7, 2009 Brian Orelli	When the Big Guns Come In, You Get Blasted Larger drug companies may want to gobble up smaller drug firms like Allos Therapeutics and Gloucester Pharmaceuticals.
InternetNews December 4, 2009	Laptop Thief Nabs Hospital Patient Data It's the latest incident in which a lost or missing laptop leads to criminals gaining access to sensitive data.
The Motley Fool December 4, 2009 Brian Orelli	Our Final Offer (Maybe)! That's a FACT! Biogen ups its bid for Facet.
The Motley Fool December 4, 2009 Brian Orelli	After Rising 500%, What Did You Expect? A nice licensing deal, but the stock was too high to begin with. The development-stage drugmaker Targacept licensed its lead product, depression treatment TC-5214, to AstraZeneca yesterday.
<Older 6071-6080 Newer> Return to current articles.